WO2004083413A1 - 器官形成方法 - Google Patents
器官形成方法 Download PDFInfo
- Publication number
- WO2004083413A1 WO2004083413A1 PCT/JP2004/003578 JP2004003578W WO2004083413A1 WO 2004083413 A1 WO2004083413 A1 WO 2004083413A1 JP 2004003578 W JP2004003578 W JP 2004003578W WO 2004083413 A1 WO2004083413 A1 WO 2004083413A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- tetrahydro
- retinoic acid
- benzoic acid
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
Definitions
- the present invention relates to a method of forming an organ from undifferentiated vertebrate cells.
- Vertebrate organisms including humans, have a great number of organs and tissues.
- organ formation from undifferentiated cells For inflammation 'regeneration, Vol. 22, 21, 2002, and spleen organogenesis, refer to JP-A-2001-299335 and JP-A-2001-333770.
- undifferentiated cells which are animal caps (pluripotent cell clusters) at the blastula stage of a newt, with a high concentration of activin can form a rhythmically beating heart with a 60% formation rate. .
- retinoic acid is an active metabolite of vitamin A. It acts to differentiate developing immature cells into mature cells with unique functions, promotes cell growth and maintains life. It has a very important physiological action such as action.
- Such compounds having retinoic acid and retinoic acid-like biological activity are collectively referred to as "retinoides”.
- Retinoic acid is a regulator of embryonic patterning along the anterior-posterior axis (Nature 340, 140-144, 1989, Development 112, 945-958, 1991, Dev. Biol. 192, 1-16, 1997, Zool. Sci. 15, 879-886, 1998), and it has been abandoned that this retinoic acid retrogrades anterior nervous tissue in the Xenopus embryo and has an effect on mesoderm development (Genes Dev. 5, 175-187, 1998). 1991, Develop. Growth. Differ. 35, 123-128, 1993).
- mesoderm tissues such as notochord, muscle, mesenchymal and luminal epithelium
- activin Rost. Biol. 198, 330-335, 1990, Nature 347, 391-394, 1990, Roux's Arch. Dev. Biol. 200, 230-233, 1991
- retinoic acid co-processed with activin.
- mesoderm tissues such as notochords, muscles and pronephros differentiated from animal cap cells are lateralized (Develop. Growth. Differ. 35, 123-128, 1993) Have been reported.
- retinoic acid The effects of retinoic acid on endodermal organs have been reported by Dixon et al. When treating retinoic acid embryos at stages 22-32 with retinoic acid results in abnormal morphology of digestive organs such as the intestine, liver, and stomach. However, it has also been reported that the knees of embryos at the stage 22-32 treated with retinoic acid form normally and that the expression of the endoderm-specific marker XlHbox8 is not affected ( Dev. Genes Evol. 208, 318-326, 1998).
- all-trans retinoic acid is a retinoic acid receptor (Evans, RM, Science, 240, p. 889, 1988) belonging to the superfamily (Evans, RM). (MR) as a ligand to control the proliferation, differentiation, or death of animal cells (Petkovich, M., et al., Nature, 330, pp. 444-450, 1987). It is known that an upper pancreas can be formed in vitro by using this oleno 'trans' retinoic acid or by using a combination of all-trans retinoic acid and activin (Japanese Patent Application Publication No. 2001-299335 and No. 2001-333770).
- RXR retinoid X receptor
- 9-cis-retinoic acid as a natural ligand; this compound is also a ligand of RAR
- RXR forms a dimer with MR and regulates the expression of retinoic acid bioactivity by initiating or suppressing gene transcription (angelsdorf, DJ et al., Nature, 345). , pp. 224-229).
- Various agonists or antagonists capable of binding to RXR are known (eg, HX600 described in JP-A-10-59951, and HX603 described in the same publication as antagonists). Whether or not organs can be formed from undifferentiated cells using a ligand that binds to RXR has not been known at all. Disclosure of the invention
- An object of the present invention is to provide a means for forming a desired organ from undifferentiated vertebrate cells.
- the present inventors have conducted intensive studies to solve the above-described problems, and as a result, have found that organs such as heart and nerve can be formed from undifferentiated cells using a ligand that binds to RXR.
- the present inventors have found that the use of RAR ligands that do not substantially bind to retinoic acid receptor (RAR) subtype y and activin as RAR ligands enables the formation of highly differentiated knees from undifferentiated cells.
- RAR retinoic acid receptor
- a method for forming organs and / or tissues in vitro from undifferentiated vertebrate cells which comprises culturing undifferentiated cells of a vertebrate animal in the presence of a retinoic acid X receptor ligand.
- the above method wherein the retinoic acid X receptor ligand is an agonist or antagonist of retinoic acid X receptor, wherein the organ and / or tissue formed is A method as described above is provided which is heart, smooth muscle tissue, or adipocyte tissue.
- the present invention also provides a differentiation inducer for forming an organ and / or tissue from undifferentiated vertebrate cells in vitro, which comprises a retinoic acid X receptor ligand. You.
- a method of forming a knee in vitro from undifferentiated cells of a vertebrate or a method of forming a tissue having spleen morphology and function in vitro from undifferentiated cells of a vertebrate, comprising the steps of: Undifferentiated cells of retinoic acid receptor subtype
- a method comprising culturing in the presence of a retinoic acid receptor ligand and activin that does not substantially bind to 7.
- the above-mentioned retinoic acid receptor ligand is 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) pyruvamoyl] benzoic acid
- a method as described above which is an acid.
- a differentiation inducer for in vitro forming a knee or a tissue having a morphology and function of the knee from undifferentiated cells of a vertebrate, wherein the retinoic acid does not substantially bind to the retinoic acid receptor subtype ⁇ .
- the present invention also provides a differentiation inducer containing a receptor ligand.
- the present invention provides an organ and / or tissue formed by the above method.
- FIG. 1 is a photograph showing ES cell colonies.
- FIG. 2 is a photograph showing an embryoid body formed in a Pacteria dish.
- FIG. 3 is a photograph showing a heart (cardiomyocyte-like cell mass) formed by the method of Example 1.
- FIG. 4 is a photograph showing a smooth muscle tissue (smooth muscle-like cell mass) formed by the method of Example 2.
- FIG. 5 is a photograph showing an adipocyte tissue formed by the method of Example 2.
- FIG. 6 is a photograph of a viscera tissue including a renal duct, endocrine and exocrine cells, etc., induced to differentiate from the embryoid body by the method of Example 3.
- FIG. 7 is a photograph showing exocrine cells of the knee induced by the method of Example 3.
- FIG. 8 is a photograph showing i3 cells (endocrine cells) of the spleen induced by the method of Example 3.
- an organ and / or tissue means an organ, a tissue, and a combination thereof constituting a vertebrate.
- an organ formed by the method of the present invention may have a structure that is usually classified as a tissue bound thereto, and a method of forming such a conjugate is also included in the scope of the present invention. You. Further, two or more kinds of organs and tissues may be simultaneously formed by the method of the present invention. Examples of the organ include, for example, a heart, a knee, a kidney, and the like, and examples of the tissue include a nerve tissue, a smooth muscle tissue, and an adipocyte tissue, but are not limited thereto.
- the organ is preferably a heart or a spleen, and the tissue is preferably a smooth muscle tissue or an adipose tissue.
- Retinoic acid X receptor ligands include retinoic acid X receptor agonists (hereinafter sometimes referred to as RXR agonists) and retinoic acid X receptor antagonists (hereinafter referred to as RXR ligands). RXR antagonists). Whether a substance can be an RXR ligand is determined, for example, by Boehm, MF, et al., J. Med.
- RXR ligands include, for example, JP-A-9-100270, JP-A-10-59951, JP-A-10-114757, JP-A-10-237050, and JP-A-10-237050.
- RXR ligands Compounds that can act as RXR ligands among compounds described in JP-338658, JP-A-2000-273079, International Publication WO99 / 24415, and the like can be used, but are not limited thereto.
- RXR ligands may be used in combination of two or more.
- RXR antagonists can be used in combination.
- RXR agonist for example,
- RXR agonists and RXR antagonists are not limited to these specific compounds.
- vertebrate undifferentiated cells such as birds, reptiles, and amphibians can be used in addition to mammals.
- undifferentiated cells stem cells such as embryonic stem cells, hematopoietic stem cells, and basal cells of small intestinal crypts, as well as cell populations such as animal cap embryoid bodies of middle to late blastulas can be used. it can.
- the term "undifferentiated cells” as used herein should not be interpreted as excluding a cell population formed by two or more cells.
- Organ and Z or tissue formation by the method of the present invention can be performed by various methods used in the art as a method for forming an organ and Z or tissue from undifferentiated cells.
- a method for forming an organ and Z or tissue from undifferentiated cells For example, since methods for forming a knee from undifferentiated cells are described in detail in JP-A-2001-299335 and JP-A-2001-333770, those skilled in the art will refer to these publications while referring to these publications.
- the desired organ can be formed from the undifferentiated cells according to the method of the Examples of the present specification.
- the disclosures of JP-A-2001-299335 and JP-A-2001-333770 are all incorporated herein by reference.
- organogenesis can be performed by culturing the embryoid body derived from embryonic stem cells in the presence of an appropriate concentration of RXR ligand for one to several days. After culturing for one to several days in the presence of the RXR ligand, further culturing may be continued in the absence of the RXR ligand.
- concentration of the RXR ligand is not particularly limited, but can be appropriately selected, for example, from a range of about IX 10 to 12 to 1 ⁇ 10 ⁇ 3 M.
- the method of the present invention is in. Although it can be performed in an in vitro environment, the term in vitro is used herein to mean “in vitro” and should not be construed as limiting in any way.
- embryonic stem cells include 129 mouse E14 cells (ATCC #; CRL-1821) established by Hooper or C57BL mice B6 (ATCC #;) established by Ledermann and Burki. SCRC-1002) can be used. These were lined from the inner cell mass of mouse blastocysts.
- the types of embryonic stem cells are not limited to these. In general, the passage number of embryonic stem cells does not affect the ability to form organs and / or tissues.
- the RXR ligand solution is diluted with a medium as needed and added to the medium, followed by treatment for one to several days.
- a solvent for dissolving the RXR ligand water, physiological saline, a buffer, an organic solvent such as dimethyl sulfoxide, or a mixture of water and an organic solvent can also be used.
- a manore well plate coated with laminin, collagen I or matrigenolecoat (Biocoat, manufactured by Becton Dickinson) can be used, if necessary. After this treatment, it is desirable to record the state of cell differentiation after a certain period of time.
- the bone morphogenic proteins (BMP) BMP2 / 4 and BMP6 / 7 have the strength of FGF, activin, folistatin, bidelogenin, insulin, gnore gon, concanavalin, cytochalasin, and cadaverine.
- treatment can be performed using an inducing factor such as, cell growth factor, or cytodynamics.
- the present invention provides a method for extracting a knee from undifferentiated vertebrate cells.
- a method for in vitro formation of a vertebrate undifferentiated cell or a tissue having morphology and function of a knee from vertebrate undifferentiated cells comprising converting vertebrate undifferentiated cells to retinoic acid receptor subtype ⁇ . Culturing in the presence of a retinoic acid receptor ligand and activin which do not bind specifically.
- Retinoic acid receptor (MR) ligand (hereinafter sometimes referred to as RAR ligand) binds to receptors required for all-trans-retinoic acid or 9-cis-retinoic acid to exert physiological effects. It is a compound having properties.
- an action similar to retinoic acid eg, a cell differentiation action, a cell growth promoting action, and a life sustaining action
- a retinoic acid receptor agonist hereinafter sometimes referred to as a RAR agonist
- RAR ligands exhibiting at least one action of the above) or a part thereof can be used. Whether or not it is a RAR ligand can be easily determined by various methods described in M.
- RAR ligand used in the method of the present invention binds to RAR subtype a (RARa) and subtype 3 (RAR ⁇ ), or substantially binds to subtype y (RAR ⁇ ). Not a RAR ligand. Binding to the retinoic acid receptor subtype can be easily confirmed by the method described in the literature (H. de The, and A. Dejean, "Retinoids, 10 years on, Basel, Karger, pp.
- RAR ligand having the above properties for example, a RAR agonist having a basic skeleton of phenyl-substituted rubamoyl benzoic acid or phenyl-substituted carboxamide benzoic acid can be used.
- a RAR agonist having a basic skeleton of phenyl-substituted rubamoyl benzoic acid or phenyl-substituted carboxamide benzoic acid can be used.
- RAR ligands based on benzoic acid or phenyl-substituted carboxamide benzoic acid are known
- the term basic skeleton means the main chemical structure to which one or more optional substituents are attached.
- the phenyl group to be substituted with the carbamoyl group or the carpoxamide group has one or more substituents.
- a lower alkyl group can be used (in the present specification, lower means about 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms).
- a linear or branched alkyl group is preferable, and Specific examples include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group, and a tert-butyl group.
- Examples of the substituent on the phenyl group include a lower alkoxy group such as a methoxy group, a halogen atom (a halogen atom may be any of a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom). Examples thereof include lower alkyl-substituted silyl groups such as a trimethylsilyl group.
- Examples of the phenyl group to be substituted with the carbamoyl group include a phenyl group substituted with 2 to 4 lower alkyl groups or a phenyl group substituted with 1 or 2 tri-lower alkylsilyl groups. More preferably, a phenyl group substituted with 2 to 4 alkyl groups or a phenyl group substituted with 2 trimethylsilyl groups is more preferable.
- the two lower alkyl groups to be substituted on the above phenyl group When two lower alkyl groups to be substituted on the above phenyl group are adjacent to each other, the two lower alkyl groups together form a 5-membered ring together with the ring-forming carbon atom of the phenyl group to which they are bonded.
- One or two rings preferably one ring, may be formed.
- the ring thus formed may be saturated or unsaturated, and the ring may be substituted with one or more lower alkyl groups such as a methyl group and an ethyl group.
- the formed ring may be substituted with preferably 2 to 4 methyl groups, more preferably 4 methyl groups.
- two adjacent lower alkyl groups substituted on a phenyl ring together form a 5,6,7,8-tetrahydronaphthalene ring ⁇ 5,5,8,8-tetramethyl-5,6,7 It is preferred that a 1,8-tetrahydronaphthalene ring or the like is formed.
- RAR ligands include, for example, the following general formula (I):
- R 2 , R 3 , R 4 , and R 5 each independently represent a hydrogen atom, a lower alkyl group, or a lower alkyl-substituted silyl group; and, R 2 , R 3 , R, and R 5 When any two of the adjacent groups are lower alkyl groups, they may be joined together to form a 5- or 6-membered ring with the carbon atom on the benzene ring to which they are attached. Often
- the ring may have one or more alkyl groups
- X represents -C0NH- or -NHC0-.
- the lower alkyl group represented by R 2 , R 3 , R and R 5 is preferably a straight or branched chain having about 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms.
- a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n -butyl group, a sec -butyl group, or a teri; -butyl group can be used.
- One or more optional substituents may be present on the lower alkyl group. Examples of the substituent include a hydroxyl group, a lower alkoxy group, and a halogen atom.
- Examples of the lower alkyl-substituted silyl group represented by R 2 , R 2 , R and R 5 include a trimethylsilyl group.
- Two adjacent lower alkyl groups selected from the group consisting of R ⁇ , R 3 , R 4 , and R 5 are joined together to form a 5- or 6-membered ring together with the carbon atom on the benzene ring to which they are attached.
- One or two, preferably one, may be formed.
- the ring thus formed may be saturated, partially saturated, or aromatic, and may have one or more alkyl groups on the ring.
- As the alkyl group which can be substituted on the ring a linear or branched alkyl group having about 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms can be used.
- a methyl group, an ethyl group, and the like can be used, and preferably 2 to 4 methyl groups, more preferably 4 methyl groups may be substituted.
- RAR ligands suitably used in the method of the present invention include: 4 - (2, 4-bis-trimethylsilyl-off We sulfonyl Cal poke Sami Do) benzoate (... Am 5 5 5 s, J. Med Chem, 33, pp 1430-1437, 1990) or 4- [(5, 6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthaleyl) lubamoyl] Benzoic acid (Am80, Hashimoto, Y., Cell struct. Funct., 16, pp. 113-123, 1991; Hashimoto, Y. occidentalet al., Biochem. Biophys. Res. Commun., 166, pp. 1300-1307, 1990), and a particularly preferred RAR ligand is Am80.
- the method of the present invention comprises a step of culturing undifferentiated vertebrate cells in the presence of the above-mentioned MR ligand and activin.
- the undifferentiated cells and the culture method those described above can be used.
- an inducer other than activin for example, FGF
- an organ which is substantially completed as a spleen or a highly differentiated tissue having substantially the form and function of a spleen is obtained. There is a feature that can be obtained.
- concentration of RAR ligands ⁇ Pi Akuchibin is Ru appropriately selectable der, for example, the concentration of the RAR ligand and 1 X 10- 12 ⁇ 1 X 10- 3 M in the range of about, 0.1 the concentration of ⁇ click Chibin 1 It can be in the range of about 1000 ng / ml.
- a combination of the MR ligand and the RXR ligand can be used.
- the organ and / or tissue formed by the method of the present invention can be used for screening of a medicine having the organ and / or tissue as a direct or indirect action point.
- a heart is formed by the method of the present invention, the formed heart has a constant pulsatile rhythm over a long period of time.
- using this heart to screen for a drug that acts to increase or decrease heart rate Is possible.
- Example 1 Heart formation using RXR ligand
- E14 cells (ATCC #; CRL-1821) of a 29 strain mouse or B6 (ATCC #; SCRC-1002) of a C57BL strain mouse were used. Inoculate 0.1% gelatin-coated culture dishes with mouse fetal fibroblasts prepared from 13-day embryo mice, 12% fetal calf serum (Giboco), 100 U / ml penicillin (Sigma), 100 ⁇ l The cells were cultured for 24 hours in a medium containing g / ml streptomycin (Sigma).
- the cells were treated with 10 ⁇ g / ml mitomycin C (MMC; Sigma) for 4 hours to inhibit cell division, then washed twice with phosphate buffered saline (PBS) to remove MMC.
- PBS phosphate buffered saline
- the medium for ES cells includes 15% fetal calf serum for ES (Giboco), 2 mM L-glutamine (Gibco), MEM non-essential amino acid (Sigma), 1 mM sodium pyruvate (Giboco), 0.0007% ] D-MEM containing 3-mercaptoethanore (Sigma), 1000 U / ml Leukemia inhibiting factor (Chemicon) N 100 U / ml penicillin (Sigma), 100 ⁇ g / ml streptomycin (Sigma) over scan, Giboco) used, and cultured at 37 ° C for at C0 2 incubator (5% C0 2, 100% humidity), the culture medium was exchanged daily.
- the subculture was performed 72 hours after seeding the ES cells.
- Feeder cells mouse fetal fibroblasts treated with C were seeded 24 hours before in a gelatin-coated culture dish, and then completely dissociated by 0.05% trypsin-0.02% EDTA treatment.
- ES cells were seeded to form colonies (see Fig. 1). After inoculation of the ES cells, the cells were cultured for 3 days to form a colony. The colony was isolated by pipetting, and then inoculated on a culture dish for bacteria having extremely low cell adhesion.
- the medium used was D-MEM (high glucose) containing 15% Knockout SR (SR, Giboco), 100 U / ml penicillin, and lOO ⁇ g / ml streptomycin.
- SR Knockout SR
- the embryoid bodies 0.1% gelatin coated 2 ⁇ El plates (TPP Co.) to 4 were seeded to six Dzudzu, PA024 of 1 X 10- 5 M as RXR ligand (2 - [N-cyclopropyl Mechinore -N- (5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-yl) [Mino] pyrimidine-5-carboxylic acid) was added and cultured for 2 days.
- a cell mass of autonomically beating cardiomyocytes was formed 48 to 72 hours after the start of treatment as 0 hour (Fig. 3). The frequency of appearance of this cell mass was 0.2 cell mass / embryoid body.
- Example 1 In the same manner after treatment with 1 X 10- 5 ⁇ 2 ⁇ 1 ( ⁇ of 6 ⁇ ⁇ 024, smooth muscle-like cells were formed by further continued when about 1-2 weeks culture. The cell mass, It showed slow peristalsis, and the frequency was 0.1-0.2 cell masses (Fig. 4) In addition, adipocytes began to appear in about 2 weeks and were cultured for 20 days about 30-40% of the total when ever became adipocytes. in terms of the numerical value per embryoid bodies was almost 100%. All-trans retinoic fin acid treatment control group (1 X 10- 5 ⁇ The amount of adipocytes formed was 2-3 times higher in the ⁇ 024 treatment group than in the case of ⁇ 024) (Fig. 5) Example 3: Combination of RAR ligands Am80 and activin to form viscera
- Mouse embryonic fibroblast primary mouse treated with mitomycin-C (10 / ig / ml, 3 hr) to inhibit cell division on a 10-cm culture dish (TPP) coated with 1% gelatin.
- Embryonic fibroblast PMEF was inoculated, cultured for at least one day, and used as a feeder layer.
- ES-E14TG2a ATCC # CRL-182l
- Medium for ES cells is 15% fetal bovine serum (FBS, Gibco), non-essential amino acids, 0.007% 13-mercaptoethanol, 1000 U / ml Leukemia inhibiting factor (Chemicon), 100 U / ml Performed in DMEM (high glucose, Gibco) containing penicillin and 0.1 mg / ml streptomycin. The medium was changed every day.
- EBs were formed from colonies 72 hours after seeding the above ES cells. After the ES cell colonies were washed once with Dulbecco's PBS, 1 mg / ml collagenase / dispase (Roche) was added at 1 ml per 10 cm dish, and the cells were treated at room temperature for 30 to 40 seconds. When about 50% of the knee has emerged in the solution, it contains Embryoid medium (EM), 15% Knockout Serum Replacement (KSR, Gibco), 100 U / ml penicillin, 0.1 mg / ml streptomycin DMEM (high glucose) was added at 13 ml per 10 cm culture dish to collect colonies.
- EM Embryoid medium
- KSR Knockout Serum Replacement
- the media was collected in a 15 ml tube without physical damage to the ES cell colonies, and allowed to stand for about 5 minutes. When the colonies settled out, the medium was removed and resuspended in EM.
- the ES cells were seeded on a low-adhesion culture 10 cm dish (Corning or Nunc) and cultured in a floating system. The medium was changed once every two days, and on the fourth day, it was used as an embryoid body (EB) in the experiment.
- EB embryoid body
- EBs having a diameter of about 500 ⁇ m were transferred to a low-adhesion 24-well plate (Corning or Nunc) together with 100 ⁇ l of medium, one at a time, while observing with a stereomicroscope.
- a differentiation-inducing medium containing 900 ⁇ l of activin / Am80 (4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthaluryl) potumbamoyl] benzoic acid) : DMEM (high darcos) containing 15% KSR, 10 ng / ral activin, 0.1 ⁇ M Am80, 0.1% BSA, 100 U / ml penicillin, 0.1 mg / ml streptomycin Culture was continued for 48 hours.
- EBs were transferred to a 24-well tissue culture plate (TPP) coated with 0.1% gelatin while observing with a stereoscopic microscope, and 10% KSR, Culture was continued in DMEM (high glucose) containing 100 U / ml penicillin and 0.1 mg / ml streptomycin once every three days with a medium change.
- DMEM high glucose
- FIG. 7 is a photograph showing the induced exocrine cells of the kidney
- FIG. 8 is a photograph showing the induced ⁇ cells (endocrine cells) of the knee.
- anti-insulin antibody ⁇ anti-amylase antibody was positive, and RT-PCR analysis showed that knee-specific transcription factors such as PDX-1, PAX-4, and NGN-3 were detected from day 10 to day 14 of culture. Expression was continuously observed.
- the method of the present invention provides a means for forming a desired organ from vertebrate undifferentiated cells, for example, an organ such as a heart, a nerve, or a spleen.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/549,816 US20070161105A1 (en) | 2003-03-20 | 2004-03-17 | Method of forming organ |
CA002523986A CA2523986A1 (en) | 2003-03-20 | 2004-03-17 | Method for forming organ |
AU2004221524A AU2004221524A1 (en) | 2003-03-20 | 2004-03-17 | Method for forming organ |
JP2005503722A JP4654126B2 (ja) | 2003-03-20 | 2004-03-17 | 器官形成方法 |
EP04721319A EP1612264A4 (en) | 2003-03-20 | 2004-03-17 | ORGAN MOLDING |
US12/535,576 US8105833B2 (en) | 2003-03-20 | 2009-08-04 | Method for forming organ |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003077123 | 2003-03-20 | ||
JP2003-077123 | 2003-03-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/549,816 A-371-Of-International US20070161105A1 (en) | 2003-03-20 | 2004-03-17 | Method of forming organ |
US12/535,576 Continuation US8105833B2 (en) | 2003-03-20 | 2009-08-04 | Method for forming organ |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004083413A1 true WO2004083413A1 (ja) | 2004-09-30 |
Family
ID=33027936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/003578 WO2004083413A1 (ja) | 2003-03-20 | 2004-03-17 | 器官形成方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20070161105A1 (ja) |
EP (1) | EP1612264A4 (ja) |
JP (1) | JP4654126B2 (ja) |
AU (1) | AU2004221524A1 (ja) |
CA (1) | CA2523986A1 (ja) |
WO (1) | WO2004083413A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010503615A (ja) * | 2006-08-29 | 2010-02-04 | レインナーベート リミテッド | レチノイド化合物およびそれらの使用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220347188A1 (en) * | 2019-06-27 | 2022-11-03 | Friedrich Miescher Insitute For Biomedical Research | Promoting tissue regeneration |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1048659A1 (en) * | 1997-11-12 | 2000-11-02 | Institute of Medicinal Molecular Design, Inc. | Retinoid receptor agonists |
EP1285961A1 (en) * | 2000-05-31 | 2003-02-26 | Japan Science and Technology Corporation | Method of forming vertebrate pancreas in vitro |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5929069A (en) * | 1995-09-21 | 1999-07-27 | Institute Of Medicinal Molecular Design, Inc. | Compounds activating pharmacological effects of retinoids |
JP3865829B2 (ja) * | 1995-09-21 | 2007-01-10 | 株式会社医薬分子設計研究所 | レチノイド作用増強性化合物 |
JPH09100270A (ja) * | 1995-10-03 | 1997-04-15 | Koichi Shudo | レチノイドアンタゴニスト |
JP4005160B2 (ja) * | 1996-10-11 | 2007-11-07 | 紘一 首藤 | レチノイドアンタゴニスト |
JPH10237050A (ja) * | 1997-02-28 | 1998-09-08 | Iyaku Bunshi Sekkei Kenkyusho:Kk | レチノイド化合物 |
JPH10338658A (ja) * | 1997-04-08 | 1998-12-22 | Hoechst Marion Roussel Kk | レチノイド作用調節剤 |
JP2004504834A (ja) * | 2000-08-01 | 2004-02-19 | イスム リサーチ ディベロップメント カンパニー | 胚性細胞の定方向分化 |
CA2420962C (en) | 2000-09-01 | 2009-11-24 | Toko Pharmaceutical Ind. Co., Ltd. | Method for preparing crystal of 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid |
EP1401282A4 (en) * | 2001-05-25 | 2005-03-30 | Cythera Inc | DIFFERENTIATION OF STEM CELLS |
CA2482147A1 (en) | 2002-04-22 | 2003-10-30 | Research Foundation Itsuu Laboratory | Medicament for therapeutic treatment of vascular disease |
US20070049579A1 (en) | 2005-03-04 | 2007-03-01 | Ryozo Nagai | Medicament having neovascularization promoting action |
-
2004
- 2004-03-17 JP JP2005503722A patent/JP4654126B2/ja not_active Expired - Fee Related
- 2004-03-17 US US10/549,816 patent/US20070161105A1/en not_active Abandoned
- 2004-03-17 AU AU2004221524A patent/AU2004221524A1/en not_active Abandoned
- 2004-03-17 CA CA002523986A patent/CA2523986A1/en not_active Abandoned
- 2004-03-17 EP EP04721319A patent/EP1612264A4/en not_active Withdrawn
- 2004-03-17 WO PCT/JP2004/003578 patent/WO2004083413A1/ja not_active Application Discontinuation
-
2009
- 2009-08-04 US US12/535,576 patent/US8105833B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1048659A1 (en) * | 1997-11-12 | 2000-11-02 | Institute of Medicinal Molecular Design, Inc. | Retinoid receptor agonists |
EP1285961A1 (en) * | 2000-05-31 | 2003-02-26 | Japan Science and Technology Corporation | Method of forming vertebrate pancreas in vitro |
Non-Patent Citations (7)
Title |
---|
KIM M.J. ET AL: "Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and developement", MOLECULAR GENETICS AND METABOLISM, vol. 74, no. 3, 2001, pages 362 - 369, XP002979935 * |
MILLION K. ET AL: "Effects of retinoic acid receptor-selective agonists on human nasal epithelial cell differentionation", AMERICAN JOURNAL OF RESPIRATORY AND MOLECULAR BIOLOGY, vol. 25, no. 6, 2001, pages 744 - 750, XP001157307 * |
NAGY L. ET AL: "Activation of retinoid X receptors induces apoptosis in HL-60 cell lines", MOLECULAR AND CELLULAR BIOLOGY, vol. 15, no. 7, 1995, pages 3540 - 3551, XP002979937 * |
See also references of EP1612264A4 * |
SEWTER C.P. ET AL: "Regional differences in the response of human pre-adipocytes to PPARgamma and PXRalpha agonists", DIABETES, vol. 51, no. 3, March 2002 (2002-03-01), pages 718 - 723, XP002979934 * |
SHIBAKURA M. ET AL: "A retinoic acid receptor-alpha (RAR alpha) selective agonist modulates procoagulant activity of acute promyelocytic cells and induces their differentiation into neutrophils", BLOOD, vol. 91, no. 2, 1998, pages 724 - 725, XP002979936 * |
WESTON A.D. ET AL: "Regulation of skeletal progenitor differention by the BMP and retinoid signaling pathways", THE JOURNAL OF CELL BIOLOGY, vol. 148, no. 4, 2000, pages 679 - 690, XP002244029 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010503615A (ja) * | 2006-08-29 | 2010-02-04 | レインナーベート リミテッド | レチノイド化合物およびそれらの使用 |
Also Published As
Publication number | Publication date |
---|---|
JP4654126B2 (ja) | 2011-03-16 |
CA2523986A1 (en) | 2004-09-30 |
EP1612264A4 (en) | 2006-05-31 |
US20090291492A1 (en) | 2009-11-26 |
US8105833B2 (en) | 2012-01-31 |
AU2004221524A1 (en) | 2004-09-30 |
JPWO2004083413A1 (ja) | 2006-06-22 |
EP1612264A1 (en) | 2006-01-04 |
US20070161105A1 (en) | 2007-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tani et al. | Understanding paraxial mesoderm development and sclerotome specification for skeletal repair | |
Broun et al. | Cngsc, a homologue of goosecoid, participates in the patterning of the head, and is expressed in the organizer region of Hydra | |
JP4971131B2 (ja) | 再生医学に適した高純度心筋細胞調製物を作製するための方法 | |
US8883504B2 (en) | Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line | |
Mezentseva et al. | The brown adipocyte differentiation pathway in birds: an evolutionary road not taken | |
CN109104869A (zh) | 表达选自由cd201、cd46、cd56、cd147和cd165组成的组中的至少1种细胞表面标记物的间充质干细胞及其制备方法、以及包含上述间充质干细胞的药物组合物及其制备方法 | |
CA2324350A1 (en) | Cardiac-derived stem cells | |
KR20090109564A (ko) | 간엽계 세포의 제조방법, 이빨의 제조방법 및 이빨 형성용 간엽계 세포 | |
Mikami et al. | Current status of drug therapies for osteoporosis and the search for stem cells adapted for bone regenerative medicine | |
KR100980005B1 (ko) | 배아줄기세포를 심근세포로 분화 유도하는 방법 | |
JP2023525297A (ja) | 幹細胞をドーパミン作動性前駆細胞に分化させるための方法 | |
Kawamura et al. | Cellular and molecular characterization of transdifferentiation in the process of morphallaxis of budding tunicates | |
US8105833B2 (en) | Method for forming organ | |
JP6453753B2 (ja) | 脂肪組織細胞 | |
Asashima et al. | Elucidation of the role of activin in organogenesis using a multiple organ induction system with amphibian and mouse undifferentiated cells in vitro | |
Kronmiller et al. | Instruction by retinoic acid of incisor morphology in the mouse embryonic mandible | |
KR20050115926A (ko) | 줄기 세포의 분화 유도 및 분화능의 제어 | |
Xie et al. | Peroxisome proliferator-activated receptor (PPAR) in regenerative medicine: molecular mechanism for PPAR in stem cells’ adipocyte differentiation | |
JP2005013152A (ja) | 細胞分化抑制剤及びこれを用いた細胞培養方法、培養液、培養された細胞 | |
Hassel et al. | Signals and signal-transduction systems in the control of development in Hydra and Hydractinia. | |
US10662407B2 (en) | Method for controlling differentiation of embryonic stem cells into adipocytes or kidney precursor cells by regulating SIRT1 expression | |
JP2000157260A (ja) | 初代前駆脂肪細胞の分化誘導方法及びその分化用培地 | |
WO2007004469A1 (ja) | 前脂肪細胞の成熟脂肪細胞への分化培養方法、ならびにその分化過程に影響する物質のスクリーニング | |
JP2008141973A (ja) | 心筋細胞の培養増殖法 | |
JP2006180763A (ja) | 組織幹細胞増殖剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005503722 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004221524 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004721319 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2523986 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2004221524 Country of ref document: AU Date of ref document: 20040317 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004221524 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004721319 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007161105 Country of ref document: US Ref document number: 10549816 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10549816 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004721319 Country of ref document: EP |